Want to join the conversation?
$MNK said it submitted Investigational New Drug (IND) application for Synacthen Depot to the U.S. Food and Drug Administration (FDA). The company will pursue an indication for the drug in treatment of Duchenne muscular dystrophy (DMD). $MNK expects continued significant R&D investments in Synacthen Depot as this development program progresses.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.